New pill-chemo combo takes on hard-to-treat cancers

NCT ID NCT07667400

Not yet recruiting Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 35 times

Summary

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About 120 adults will take part, receiving the drugs in 3-week cycles for up to 6 cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SX-682 (a tablet) and docetaxel (a chemotherapy drug given by IV)
What this could lead to: If it works, this combination could offer a new treatment option for people with head/neck or prostate cancers that have spread or come back.
What could go wrong: This is an early-phase trial (Phase I/II) with only 120 participants, so it may not show enough benefit or could have side effects. The drugs may not work for all cancer types studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma carcinoma castration-resistant prostate carcinoma head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma hypopharyngeal carcinoma hypopharynx cancer laryngeal carcinoma laryngeal neoplasm metastatic prostate carcinoma nasopharyngeal carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma paranasal sinus neoplasm Paranasal Sinus Neoplasms prostate cancer salivary gland cancer salivary gland carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA CARCINOMA OF LARYNX HEAD AND NECK CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HYPOPHARYNGEAL CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CANCER NASOPHARYNGEAL CARCINOMA ORAL SQUAMOUS CELL CARCINOMA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA PARANASAL SINUS NEOPLASMS PROSTATE CANCER SALIVARY GLAND CANCER

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.